Peter J. Houghton

40.0k citations

571 papers · 28.8k indexed · 3 hit papers · h-index 86

Molecular Biology top 0.1%
Oncology top 0.1%
Pulmonary and Respiratory Medicine top 0.5%
Cancer Research top 0.2%
Plant Science top 0.5%

Co-authors: Mary‐Ann Bjornsti Janet A. Houghton Christopher L. Morton John Easton Shile Huang Malcolm A. Smith Raushan T. Kurmasheva Pulok K. Mukherjee
Topics: Neuroblastoma Research and Treatments (95 papers)Cancer therapeutics and mechanisms (95 papers)Sarcoma Diagnosis and Treatment (61 papers)
Cited by: Oncology Molecular Biology Complementary and alternative medicine
Journals: Nature Science Proceedings of the National Academy of Sciences
Partner nations: United States United Kingdom Australia

In The Last Decade

Peter J. Houghton

561 papers receiving 27.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The tor pathway: a target for cancer therapy

2004 1.1k citations Peter J. Houghton et al. profile →
Phosphorylation of the Translational Repressor PHAS-I by the Mammalian Target of Rapamycin

1997 801 citations Peter J. Houghton et al. profile →
Acetylcholinesterase inhibitors from plants

2007 668 citations Peter J. Houghton et al. profile →

Peers

Countries citing papers authored by Peter J. Houghton

Since Specialization

Citations

This map shows the geographic impact of Peter J. Houghton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J. Houghton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J. Houghton more than expected).

Fields of papers citing papers by Peter J. Houghton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter J. Houghton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J. Houghton. The network helps show where Peter J. Houghton may publish in the future.

Co-authorship network of co-authors of Peter J. Houghton

This figure shows the co-authorship network connecting the top 25 collaborators of Peter J. Houghton. A scholar is included among the top collaborators of Peter J. Houghton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J. Houghton. Peter J. Houghton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sensitization to Ionizing Radiation by MEK Inhibition Is Dependent on SNAI2 in Fusion-Negative Rhabdomyosarcoma 2022 ·Molecular Cancer Therapeutics ·(unknown),(unknown),(unknown),Prethish Sreenivas,(unknown),(unknown),Angelina V. Vaseva,Peter J. Houghton,Myron S. Ignatius	0
2	A Very Long-Acting PARP Inhibitor Suppresses Cancer Cell Growth in DNA Repair-Deficient Tumor Models 2020 ·Cancer Research ·Shaun D. Fontaine,Gary W. Ashley,Peter J. Houghton,Raushan T. Kurmasheva,Morgan E. Diolaiti,Alan Ashworth,Cody J. Peer,(unknown),William D. Figg,Denis Beckford-Vera,Daniel V. Santi	16
3	Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts 2020 ·Clinical Cancer Research ·Andrew J. Robles,Raushan T. Kurmasheva,Abhik Bandyopadhyay,Doris A. Phelps,Stephen W. Erickson,Zhao Lai,Dias Kurmashev,Yidong Chen,Malcolm A. Smith,Peter J. Houghton	11
4	Abemaciclib Is Active in Preclinical Models of Ewing Sarcoma via Multipronged Regulation of Cell Cycle, DNA Methylation, and Interferon Pathway Signaling 2018 ·Clinical Cancer Research ·Michele Dowless,Caitlin D. Lowery,Terry J. Shackleford,(unknown),Jennifer Stephens,(unknown),Wayne Blosser,Simone Gupta,Julie Stewart,Yue Webster,Jack Dempsey,(unknown),Philip J. Ebert,Philip W. Iversen,Jonathan B. Olsen,Xueqian Gong,Sean G. Buchanan,Peter J. Houghton,Louis F. Stancato	47
5	Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL 2017 ·Clinical Cancer Research ·(unknown),Jennifer Richmond,Kathryn Evans,Hernán Carol,Duohui Jing,Raushan T. Kurmasheva,Catherine A. Billups,Peter J. Houghton,Malcolm A. Smith,Richard B. Lock	17
6	Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant 2016 ·Cancer Research ·Jennifer Richmond,Alissa K. Robbins,Kathryn Evans,Dominik Beck,Raushan T. Kurmasheva,Catherine A. Billups,Hernán Carol,Susan L. Heatley,Rosemary Sutton,Glenn M. Marshall,Deborah L. White,John E. Pimanda,Peter J. Houghton,Malcolm A. Smith,Richard B. Lock	18
7	The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma 2016 ·Molecular Cancer Therapeutics ·Hemant K. Bid,Doris A. Phelps,(unknown),Denis C. Guttridge,Jiayuh Lin,Cheryl A. London,Laurence H. Baker,Xiaokui Mo,Peter J. Houghton	66
8	Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL -Rearranged Acute Lymphoblastic Leukemia 2015 ·Clinical Cancer Research ·Jennifer Richmond,Hernán Carol,Kathryn Evans,(unknown),(unknown),Alissa K. Robbins,Claus Meyer,Nicola C. Venn,Rolf Marschalek,Michelle J. Henderson,Rosemary Sutton,Raushan T. Kurmasheva,Ursula R. Kees,Peter J. Houghton,Malcolm A. Smith,Richard B. Lock	41
9	HO-3867, a Safe STAT3 Inhibitor, Is Selectively Cytotoxic to Ovarian Cancer 2014 ·Cancer Research ·Kellie S. Rath,Shan K. Naidu,(unknown),Hemant K. Bid,Brian K. Rivera,Georgia A. McCann,Brent J. Tierney,Adam C. ElNaggar,(unknown),Gustavo Leone,Peter J. Houghton,Kálmán Hideg,Periannan Kuppusamy,David E. Cohn,Karuppaiyah Selvendiran	76
10	FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3–FOXO1 Fusion Gene 2014 ·Clinical Cancer Research ·Mamata Singh,(unknown),(unknown),Brian Geier,(unknown),Wenrui Duan,(unknown),Miguel A. Villalona‐Calero,Ning Li,(unknown),Raushan T. Kurmasheva,Changxian Shen,Gary Woods,Nikhil Sebastian,Denise Fabian,(unknown),Sue Hammond,Kamalakannan Palanichamy,Arnab Chakravarti,Peter J. Houghton	11
11	Regulation of FANCD2 by the mTOR Pathway Contributes to the Resistance of Cancer Cells to DNA Double-Strand Breaks 2013 ·Cancer Research ·Changxian Shen,(unknown),Doris A. Phelps,Hakan Çam,Christopher E. Pelloski,Qishen Pang,Peter J. Houghton	74
12	Bioactive Lipids S1P and C1P Are Prometastatic Factors in Human Rhabdomyosarcoma, and Their Tissue Levels Increase in Response to Radio/Chemotherapy 2013 ·Molecular Cancer Research ·Gabriela Schneider,(unknown),Ahmed Abdel‐Latif,Janina Ratajczak,Magdalena Maj,Maciej Tarnowski,(unknown),Peter J. Houghton,Andrew J. Morris,Axel Vater,Sven Klußmann,Magda Kucia,Mariusz Z. Ratajczak	61
13	Development, Characterization, and Reversal of Acquired Resistance to the MEK1 Inhibitor Selumetinib (AZD6244) in an In Vivo Model of Childhood Astrocytoma 2013 ·Clinical Cancer Research ·Hemant K. Bid,(unknown),Doris A. Phelps,(unknown),Linlin Xiao,Jiayuh Lin,David Capper,(unknown),Brian Geier,Mariko DeWire,Paul D. Smith,Raushan T. Kurmasheva,Xiaokui Mo,Soledad Fernández,Peter J. Houghton	49
14	ΔNp63 Promotes Pediatric Neuroblastoma and Osteosarcoma by Regulating Tumor Angiogenesis 2013 ·Cancer Research ·Hemant K. Bid,Ryan D. Roberts,Maren Cam,Anthony Audino,Raushan T. Kurmasheva,Jiayuh Lin,Peter J. Houghton,Hakan Çam	47
15	Dual Targeting of the Type 1 Insulin-like Growth Factor Receptor and Its Ligands as an Effective Antiangiogenic Strategy 2013 ·Clinical Cancer Research ·Hemant K. Bid,Cheryl A. London,(unknown),Haihong Zhong,Robert E. Hollingsworth,Soledad Fernández,Xiaokui Mo,Peter J. Houghton	18
16	The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia 2013 ·Clinical Cancer Research ·Hernán Carol,Barbara Szymanska,Kathryn Evans,Ingrid Boehm,Peter J. Houghton,Malcolm A. Smith,Richard B. Lock	57
17	Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin 2011 ·Molecular Cancer Therapeutics ·Shripad V. Bhagwat,Prafulla C. Gokhale,Andrew P. Crew,(unknown),Yan Yao,Christine Mantis,Jennifer Kahler,(unknown),Mark Bittner,Lorina Dudkin,David Epstein,Neil W. Gibson,Robert Wild,Lee D. Arnold,Peter J. Houghton,Jonathan A. Pachter	159
18	Predicting IGF-1R Therapy Response in Bone Sarcomas: Immuno-SPECT Imaging with Radiolabeled R1507 2011 ·Clinical Cancer Research ·Emmy D.G. Fleuren,Yvonne M.H. Versleijen‐Jonkers,Addy C.M. van de Luijtgaarden,Janneke D.M. Molkenboer‐Kuenen,Sandra Heskamp,Melissa H.S. Roeffen,Hanneke W.M. van Laarhoven,Peter J. Houghton,Wim J.G. Oyen,Otto C. Boerman,Winette T.A. van der Graaf	37
19	Potent Inhibition of Angiogenesis by the IGF-1 Receptor-Targeting Antibody SCH717454 Is Reversed by IGF-2 2011 ·Molecular Cancer Therapeutics ·Hemant K. Bid,Jun Zhan,Doris A. Phelps,Raushan T. Kurmasheva,Peter J. Houghton	57
20	Tyrosine Kinase Inhibitor Enhances the Bioavailability of Oral Irinotecan in Pediatric Patients With Refractory Solid Tumors 2009 ·Journal of Clinical Oncology ·Wayne L. Furman,Fariba Navid,Najat C. Daw,M. Beth McCarville,Lisa M. McGregor,Sheri L. Spunt,Carlos Rodríguez‐Galindo,John C. Panetta,Kristine R. Crews,Jianrong Wu,Amar Gajjar,Peter J. Houghton,Victor M. Santana,Clinton F. Stewart	42

About Peter J. Houghton

Peter J. Houghton is a scholar working on Oncology, Neurology and Molecular Biology, having authored 571 papers that have together received 28.8k indexed citations. Recurring topics across this work include Neuroblastoma Research and Treatments (95 papers), Cancer therapeutics and mechanisms (95 papers) and Sarcoma Diagnosis and Treatment (61 papers). The work is most often cited by research in Oncology (7.5k citations), Molecular Biology (15.6k citations) and Complementary and alternative medicine (1.8k citations). Peter J. Houghton has collaborated with scholars based in United States, United Kingdom and Australia. Frequent co-authors include Mary‐Ann Bjornsti, Janet A. Houghton, Christopher L. Morton, John Easton, Shile Huang, Malcolm A. Smith, Raushan T. Kurmasheva, Pulok K. Mukherjee, Kumar Venkatesan and Clinton F. Stewart. Their work appears in journals such as Nature, Science and Proceedings of the National Academy of Sciences.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact